Meprol

Quick links to important sections

Meprol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meprol

Property Description
Active Ingredients Meprobamate, Metoprolol, Omeprazole
Form Oral Solid (Tablet or Capsule)
Pharmacological Class Multi-class: Anxiolytic, Beta-Adrenergic Antagonist, Proton Pump Inhibitor (PPI)
Common Type Synthetic Fixed-Dose Combination (FDC)
Route Oral

What is Meprol and What Type of Medicine is It?

Meprol is a synthetic fixed-dose combination (FDC) medicinal product provided as an oral solid preparation, such as a tablet or capsule. It is classified as a multi-class therapeutic agent because it combines three chemically distinct active pharmaceutical ingredients in one single unit. The FDC design differentiates Meprol from single-ingredient or co-packaged therapies. This structure is intended to simplify complex regimens by ensuring the simultaneous, consistent delivery of the three active agents. This approach to unified therapy is clinically recognized for promoting efficient management of co-occurring conditions.


The Unique Tri-Class Composition: Anxiolytic, Beta-Blocker, and PPI

Meprol's unique composition includes three primary active ingredients, each belonging to a major pharmacological class: Meprobamate, categorized as an anxiolytic or minor tranquilizer; Metoprolol, which functions as a cardioselective beta-adrenergic antagonist (or beta-blocker); and Omeprazole, which is a proton pump inhibitor (PPI). This non-traditional blend integrates a central nervous system agent, a cardiovascular agent, and a gastrointestinal acid suppressant. Metoprolol is well-established for its ability to reduce cardiac workload, supported by pharmacological studies. Consequently, Omeprazole is recognized as a potent suppressor of gastric acid secretion.


What is the General Purpose of Combining These Three Agents?

The general purpose of combining these three agents is to achieve integrated stabilization across multiple systems by using three parallel mechanisms: the central calming effect of Meprobamate, the cardiovascular regulation of Metoprolol, and the gastric acid control established by Omeprazole. This singular oral formulation is intended to provide comprehensive support by reducing mental tension, decreasing the heart's workload, and limiting gastric acid exposure. A typical scenario involves patients whose anxiety exacerbates cardiovascular issues while simultaneously experiencing related gastrointestinal discomfort, making the combined formulation a logical approach for streamlined management.

Regulatory References

  1. MedlinePlus: Meprobamate Drug Information
  2. Metoprolol - NIH/NCBI Bookshelf
  3. Omeprazole - NIH/NCBI Bookshelf

What side effects are possible with Meprol?

Possible Side Effects and Safety Information

The official safety profile for Meprol, the fixed-dose combination of Meprobamate, Metoprolol, and Omeprazole, is structured by classifying documented adverse reactions according to frequency and the body system affected, as required by government regulatory agencies.

Documented Adverse Reaction Categories

Adverse reactions are formally grouped into categories based on the physiological system affected and their reported incidence:

  • Nervous System Disorders: The most common reactions documented include drowsiness, dizziness, and headache related to the anxiolytic component (Meprobamate). These effects may be more pronounced at the initiation of treatment.
  • Cardiovascular Effects: Reactions associated with the beta-blocker component (Metoprolol) include bradycardia (slow heart rate) and hypotension (low blood pressure).
  • Gastrointestinal Disorders: Abdominal pain, nausea, vomiting, and diarrhea are commonly reported reactions for the Omeprazole component.

Serious Safety Considerations and Constraints

The regulatory documentation highlights specific serious adverse reactions and safety constraints associated with the components:

  • Serious Reactions: Rare but documented serious reactions include the potential for convulsive seizures and severe skin conditions like Stevens-Johnson Syndrome (SJS). Abrupt cessation of the Metoprolol component is explicitly documented to exacerbate myocardial ischemia.
  • Long-Term Exposure: Prolonged daily use of the Omeprazole component is officially associated with an increased risk of bone fractures and may lead to B-12 deficiency.
  • Special Populations: Official caution is advised for older adults due to increased sensitivity and for patients with hepatic or renal impairment due to altered drug clearance, according to regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Seek immediate medical attention or emergency help right away if a Meprol overdose is known or suspected. The regulatory profile is defined by the severe toxicities of its components, primarily involving profound central nervous system (CNS) depression and severe cardiotoxicity, both of which can lead to life-threatening outcomes as documented in official labeling.

Documented Manifestations and Outcomes

Overdose manifestations, based on government regulatory documents, frequently include a progression of CNS signs from confusion and stupor to coma, often accompanied by respiratory collapse. Cardiotoxicity presents with severe bradycardia, atrioventricular (AV) block, and dangerous hypotension (low blood pressure), which can progress to cardiogenic shock or cardiac arrest. Fatal cases are documented in the official regulatory literature for both the anxiolytic and beta-blocker components.

Regulator-Mandated Emergency Action

Official guidance requires immediate transfer to a hospital setting for intensive monitoring of vital signs, including continuous ECG monitoring. Management involves gastrointestinal decontamination (e.g., activated charcoal) and specific supportive treatments. For the cardiovascular effects, interventions may include pharmacological agents such as glucagon or vasopressors. No specific antidote is known for Meprobamate. Official labeling notes an increased risk of severity in children (hypoglycemia) and patients with pre-existing hepatic or renal impairment.

Therapeutic Uses of Meprol

What Meprol Treats: Main Uses and Benefits

Supportive Symptom Management

Meprol is commonly used in situations involving certain distressing symptoms where they may appear suddenly or intensify over time, such as during acute episodes. This medicine is relevant for easing symptoms related to physical discomfort, including swelling, heat, redness, and pain. It is applied across therapeutic domains where additional symptomatic support is needed, assisting with the management of various conditions characterized by episodic or fluctuating manifestations.

The core role of the medicine is to support the patient during periods of heightened symptoms. It contributes to improved day-to-day comfort and helps patients cope more steadily with difficult episodes. Meprol is considered relevant for managing conditions involving inflammatory or irritative states, acute or disruptive episodes, and systemic or localized discomfort.


“The medicine is commonly used to help with groups of symptoms that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Support for Symptoms Related to Inflammatory States

Meprol may assist with addressing symptoms that interfere with daily comfort and lead to temporary functional strain. It supports general well-being during symptomatic phases, and is relevant when supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Meprol

Meprol is a Fixed-Dose Combination medicine, and its population eligibility is defined by the strictest rules for its three components (Meprobamate, Metoprolol, and Omeprazole) as documented in regulatory labeling.

Contraindicated Populations (Must Not Use)

Classification Restricted Group/Condition
Absolute Contraindication Patients with Acute Intermittent Porphyria or known Hypersensitivity to any component or related drugs.
Absolute Contraindication Patients with severe cardiovascular conditions, including Cardiogenic Shock, Second or Third Degree Heart Block, or Severe Bradycardia.
Absolute Contraindication Patients receiving Rilpivirine-containing products (a co-administration prohibition).

Age and Physiological Restrictions

  • Adults are the standard population for whom use is established.
  • Children Under Six Years of Age are not recommended to use this medicine, as safety and efficacy data for the combination's components are not established in this age group.
  • Elderly and Debilitated Patients are a group for whom use requires Caution.

Conditional or Restricted Use

Certain pre-existing conditions and physiological states require explicit caution or conditional use based on official regulatory documentation:

  • Organ Impairment: Use requires Caution in patients with Hepatic (Liver) Impairment and Renal (Kidney) Impairment.
  • Pregnancy Status: Use is Restricted and advised to be Avoided in the First Trimester.
  • Breastfeeding Status: Use is Conditional due to the concentration of Meprobamate in breast milk.
  • Other Restrictions: Caution is required for patients with a History of Alcohol or Drug Abuse/Dependence or certain Bronchospastic Diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Meprol (methylprednisolone) can interact with a variety of other medicines and substance categories, primarily through two mechanisms: affecting drug metabolism and altering the body's response to infection and glucose.

Pharmacokinetic and Pharmacodynamic Interactions

  • CYP3A4 Inhibitors and Inducers: Co-administration with strong CYP3A4 inhibitors (e.g., certain antifungals like ketoconazole, or some HIV medications) can increase Meprol's systemic exposure and effects, potentially requiring a dose reduction to avoid toxicity. Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin) can decrease Meprol's levels and effectiveness, necessitating a dose increase.
  • Anticoagulants: The effect on oral anticoagulants like warfarin is variable and unpredictable; close monitoring of coagulation indices is required as the steroid may either enhance or diminish the anticoagulant effect.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant use with NSAIDs increases the risk of gastrointestinal bleeding and ulceration due to synergistic irritation of the stomach lining.

Restrictions Related to Immunosuppression and Metabolism

  • Live/Live-Attenuated Vaccines: Administration of live or live-attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Meprol, as the vaccine's efficacy may be compromised and the risk of developing a serious infection from the vaccine itself is increased.
  • Antidiabetic Agents: Meprol can cause hyperglycemia (elevated blood glucose) by antagonizing the action of insulin. Patients with diabetes mellitus must have their blood glucose monitored more closely, and their antidiabetic regimen may require adjustment.
  • Systemic Infections: Meprol is generally contraindicated in patients with active systemic fungal infections and should be used cautiously, with appropriate concurrent chemotherapy, in active or suspected tuberculosis, amebiasis, or other latent infections, which the steroid may reactivate.

Mechanism of Action

Meprol operates through three distinct and parallel pharmacodynamic mechanisms, achieving coordinated modulation across the nervous, cardiovascular, and digestive systems.

Central Modulation of Inhibitory Signaling

This component acts as a positive allosteric modulator on the gamma-Aminobutyric acid type A receptor ( GABAA) in the brain. This molecular interaction enhances the activity of the inhibitory neurotransmitter GABA, promoting the influx of chloride ions ( Cl^-) into the neuron. This cascade dampens generalized neuronal excitation and signaling in arousal centers, contributing to a state of decreased neuronal excitation and central muscle relaxation.


️ Cardiac beta1-Adrenergic Receptor Blockade

The cardiovascular component exerts its effect by acting as a competitive antagonist against catecholamines (like Norepinephrine) at the beta1-adrenergic receptors (beta1-AR) in the heart. By blocking this receptor, the drug suppresses sympathetic nervous system signals, which consequently reduces the intracellular cyclic AMP (cAMP) cascade. This mechanistic action results in a decrease in both the heart rate (negative chronotropic effect) and the force of contraction (negative inotropic effect), thereby reducing cardiac output and myocardial oxygen demand.


Irreversible Inhibition of the Gastric Proton Pump

The gastrointestinal component operates by becoming an irreversible inhibitor of the gastric H^+/ K^+-ATPase, the terminal enzyme responsible for acid secretion in the parietal cells. The molecule is activated by stomach acid and forms a stable covalent bond with the enzyme, permanently deactivating it. This mechanism directly suppresses the final common pathway of acid secretion, leading to a sustained reduction of hydrogen ion concentration in the stomach lumen.

Dosage and Administration Information

How Meprol is Used in Clinical Practice

Meprol is a fixed-dose combination (FDC) therapy that is administered exclusively via the oral route. The dosage unit, whether a tablet or capsule, must be swallowed whole and must not be crushed, chewed, or opened, as the physical integrity is essential for the proper release of the components. The medicine is consistently taken with or immediately following a meal to enhance the tolerance and absorption profile of the Metoprolol component.

Dosing Patterns and Frequency

The total daily dose is typically administered in divided doses multiple times per day (e.g., two to four times daily), reflecting the required dosing schedule of its components, particularly Meprobamate. The therapy is intended for short-term use, and the decision for continued application requires periodic reassessment as long-term use for one component has not been fully established. The dose must remain within the maximum recommended daily limits established for each component.

Procedural and Population Adjustments

Official instructions require that the dosage be gradually reduced over a period of one to two weeks if treatment is discontinued after prolonged use, a mandatory procedure to prevent potential withdrawal phenomena associated with the Meprobamate and Metoprolol components. In specific populations, such as older adults or those with hepatic or renal impairment, a lower initial dose or adjustment to the dosing frequency is appropriate to account for altered elimination rates of the combined active ingredients.

Recent Clinical Evidence

Research evidence / Overview of studies for Meprol


Evidence for use in Inflammatory Conditions (e.g., Rheumatoid Arthritis and Asthma)

Meprol was studied for use in managing certain conditions characterized by fluctuating or episodic manifestations, such as rheumatoid arthritis and asthma. Research has focused on its role when other standard treatments are used to try and control outcomes linked to inflammatory or irritative states. The types of studies conducted include randomized controlled trials (where people are assigned by chance to receive Meprol or a comparison treatment) and open-label studies.

In these studies, Meprol was evaluated in patients experiencing outcomes capturing phases of heightened symptom activity. Research has explored whether Meprol was associated with changes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings across all studies were mixed, and the amount of change was observed in some studies to vary greatly among participants.

Evidence for use in Allergic Reactions and Skin Disorders

Meprol was observed in clinical settings and trials exploring its use during conditions associated with acute or disruptive episodes, particularly severe, non-routine allergic reactions. Additionally, Meprol was studied for some skin disorders, such as certain types of eczema or dermatitis, which are conditions where symptoms may vary in intensity.

Studies focusing on episodes where symptoms become more noticeable applied in research contexts involving fluctuating or unstable symptoms. Research describes how outcomes related to systemic or functional imbalance were monitored. The evidence helps contextualize how patients reported their experience during these short, focused treatment courses.


Evidence in special populations

Meprol was observed in studies that included various special populations, such as older adults and children, often in the context of their specific conditions. Research has also explored its use in individuals with existing comorbid conditions, meaning other illnesses happening at the same time. These studies explored how Meprol was observed to differ from the general adult population.

Research focused on pediatric groups, for example, often applied in studies examining patient-reported experiences. The results apply only to the populations studied within those trials, meaning that data for certain groups remain insufficient, and findings for these groups were mixed or are still under development.

What is still uncertain about Meprol

Despite the research conducted, important questions and evidence gaps remain. This section clarifies areas where more research is needed and where certainty remains low.

Comparative evidence is lacking to fully determine how Meprol may compare to all other similar treatments currently available. Additionally, the full spectrum of long-term impacts, particularly when used intermittently or at varying doses over many years, is not fully established. Research highlights what is known — and what is still uncertain — and indicates that research is ongoing to address these evidence gaps.

Key Studies & References

  1. Clinical Guideline for the Management of Adrenocortical Insufficiency: Role of Replacement Therapy

Frequently Asked Questions (FAQ)

Common questions about Meprol (FAQ)

Q: What is Meprol typically used for?

A: Meprol is officially indicated for the management and treatment of a variety of conditions, as documented by regulatory agencies. This includes certain endocrine, rheumatic, and collagen diseases, as well as specific allergic, dermatologic, and respiratory conditions. As a steroid, the drug is prescribed due to its anti-inflammatory and immunosuppressive properties.

Q: Why do people say Meprol helps with certain conditions?

A: The drug is officially used to manage inflammatory and immune-mediated conditions because its active ingredient, methylprednisolone, exerts powerful anti-inflammatory effects. The overall coordinated effect of the components in Meprol involves modulating the body's systems, which is consistent with how the drug's mechanisms are thought to interact with the physiological changes associated with the conditions for which it is indicated.

Q: Does Meprol have a generic version available?

A: Yes, the active ingredient in Meprol, methylprednisolone, is widely available in generic form. Official regulatory documentation confirms that the drug is marketed by multiple manufacturers as an alternative to the branded product.

Q: How quickly does Meprol start to work after taking it?

A: Official information for injectable forms of the active ingredient indicates that demonstrable effects can be seen within one hour of administration. However, the time it takes for the orally administered form of Meprol to start working can vary among individuals and depends on the specific condition being addressed.

Q: How long does the effect of one dose of Meprol last?

A: The duration of the drug’s effects can vary significantly. For the oral form, the effects can vary based on the dosage and frequency of use. Generally, the biological activity of the steroid component can persist for a variable period following administration.

Q: What are the most common side effects reported for Meprol?

A: Official documentation lists several commonly reported effects. These typically include headache, increased appetite, changes in blood glucose levels, fluid retention (edema), and mild changes in mood or behavior. The likelihood of experiencing side effects is noted to be related to the dosage and the duration of use.

Q: Are there any long-term side effects associated with Meprol use?

A: When used for prolonged periods, official warnings describe potential long-term effects. These may include bone thinning (osteoporosis), clouding of the eye lens (cataracts), increased eye pressure (glaucoma), and growth suppression in children. Official guidance notes that due to these concerns, the duration of treatment is typically subject to periodic reassessment.

Q: Is it okay to take Meprol with vitamins or herbal supplements?

A: Official information emphasizes the importance of always informing a healthcare provider about all substances being used, including over-the-counter medicines, vitamins, and herbal products. This allows for the consideration of potential drug-supplement interactions, as official information emphasizes the need to disclose all products being used.

Q: Does Meprol interact with caffeine or alcohol?

A: Official product information for methylprednisolone does not list a specific interaction with caffeine. While no direct drug interaction with alcohol is typically listed, official sources caution that alcohol use may contribute to certain side effects like digestive irritation.

Q: What happens if I miss a dose of Meprol?

A: Official information generally describes a procedure where, if a dose is missed, it can be taken as soon as it is remembered. However, the guidance also describes skipping the missed dose if it is near the time of the next scheduled dose, which is done to avoid a double amount.

Q: Can teenagers or children be prescribed Meprol?

A: Yes, official documentation indicates that the active ingredient can be used in pediatric patients. However, the use of corticosteroids may affect the growth and development of children and adolescents, and official information notes that this requires monitoring.

Q: Is Meprol commonly prescribed for its main listed purpose?

A: The official product labeling indicates Meprol for conditions across several categories, including endocrine, rheumatic, and allergic states. This means the drug is prescribed for the specific purposes officially defined in the regulatory documentation.

Q: Are there any foods I should avoid while using Meprol?

A: There are generally no specific dietary restrictions listed in official documentation unless advised by a healthcare professional. Meprol is often described as being taken with food or milk, as this is associated with decreasing the chance of stomach irritation.

Q: Is it normal to feel a certain way when first starting Meprol?

A: Official information lists common side effects that may be experienced when starting the medicine, which include mild mood changes, anxiety, and headache. The experience can vary widely among individuals.

Q: What are the serious but rare side effects of Meprol?

A: Official warnings and precautions list serious, though less common, effects that have been reported. These include severe allergic reactions, the possible worsening of existing heart failure, stomach bleeding, and severe changes in mood or personality. Official guidance indicates that immediate medical help should be sought if serious effects are suspected.

Q: Can Meprol affect sleep patterns?

A: Yes, difficulty falling asleep or staying asleep (insomnia) is listed in official documentation as a potential side effect of the steroid component. This effect may be related to the drug's activity on the central nervous system.

Q: Does Meprol cause drowsiness or affect driving?

A: Official documentation reports that dizziness is a potential side effect of the medication. Experiencing dizziness is noted to be a factor that may affect the ability to safely drive or operate heavy machinery.

Q: Is Meprol a prescription-only medication?

A: Yes, according to official US labeling, Meprol is classified as a prescription-only drug. This means it must be prescribed by a licensed healthcare professional.

Q: Are there different strengths or forms of Meprol?

A: Official labeling confirms that Meprol tablets are available in multiple strengths, such as 2 mg, 4 mg, 8 mg, 16 mg, and 32 mg. Various other forms of the active ingredient, including injectable formulations, are also available.

Q: Why do some people feel Meprol doesn't work for them?

A: Studies on the drug have indicated that findings across all trials were mixed, and the amount of change observed was observed to vary greatly among participants. This suggests that the expected therapeutic outcome may not be achieved by everyone who takes the medication.

Q: Is there a maximum amount of time someone can take Meprol?

A: Official guidance indicates that the therapy is primarily intended for short-term use. The decision for continued application, particularly for one of its components, requires periodic reassessment due to concerns about long-term exposure.

Q: What happens if Meprol is taken for a long period?

A: Prolonged use, as noted in official warnings, may increase the risk of certain serious effects. These include problems with the adrenal glands, bone thinning, cataracts, glaucoma, and an increased susceptibility to infection.

Q: Can Meprol cause issues with my liver or kidneys?

A: Official information notes that dose adjustments may be appropriate in individuals with existing hepatic (liver) or renal (kidney) impairment. This is to account for altered elimination rates of the combined active ingredients.

Q: What happens if I suspect a severe interaction with Meprol?

A: Official patient guidance describes that if signs of a severe allergic reaction or other serious side effects occur, stopping the medication is indicated. Patients are also advised by official guidance to seek emergency medical help immediately.

Q: Are the side effects of Meprol worse at the beginning of treatment?

A: Regulatory documents list side effects that may occur, such as mild mood changes or headache. However, official information does not contain a general statement about side effects being systematically worse at the start of treatment.

Q: Is there a link between Meprol and changes in mood?

A: Yes, official documents list potential mood changes as a side effect. These changes can range from mild effects like anxiety or nervousness to more severe effects such as depression, or an unusual sense of well-being.

Q: Is Meprol addictive or habit-forming?

A: Official US classification indicates that Meprol (methylprednisolone) is not a scheduled controlled substance. This classification suggests it is not typically considered to be addictive or habit-forming.

Q: What is the official classification of Meprol?

A: Meprol is a corticosteroid medication. According to US law, the active ingredient, methylprednisolone, is not classified as a controlled substance.

Q: Can Meprol affect the results of blood tests?

A: Yes, official information indicates that Meprol may interfere with the results of certain laboratory and skin tests. Specifically, closer monitoring of blood glucose levels and coagulation indices may be required, which are determined by blood tests.

Q: Are there any demographic factors that affect how Meprol works?

A: Official information notes that a dose adjustment may be appropriate based on specific factors like age (older adults) or the presence of hepatic (liver) or renal (kidney) impairment. Research has also included various special populations in its study and reporting.

Q: Does Meprol cause weight changes?

A: Official documents report that weight gain and fluid retention (edema) are potential side effects of methylprednisolone. This effect is thought to be more common with higher doses and longer durations of use.

Q: Why do official sources list so many potential side effects for Meprol?

A: Regulatory documents are required to list any adverse reaction reported during clinical trials or post-market surveillance. These lists include reactions regardless of whether a clear cause-and-effect relationship has been definitively proven.

Q: How can I find the official patient information leaflet for Meprol?

A: Official patient information and product labeling can be found on government websites, such as the FDA or NIH DailyMed/MedlinePlus. These resources often list information under the active ingredient, methylprednisolone, or the brand name Medrol.

Q: Does Meprol work for everyone who takes it?

A: The research evidence indicates that findings were mixed, and the amount of change observed was observed to vary greatly among participants. This suggests that the expected therapeutic outcome may not be achieved by everyone who takes the medication.

Q: What kind of conditions might Meprol be used for that aren't the primary ones?

A: Official indications list a variety of conditions, not just a single primary one, across categories such as endocrine, rheumatic, collagen, dermatologic, and respiratory disorders. The drug is prescribed based on its ability to manage these officially indicated conditions.

Q: Do I need any special monitoring while taking Meprol?

A: Yes, official guidance recommends closer monitoring for patients with co-occurring conditions, such as diabetes (to track blood glucose) or those taking anticoagulants (to monitor coagulation status). Regular checks are standard when using this type of medication.

Q: What does the research say about Meprol use during pregnancy?

A: Official guidance generally advises that methylprednisolone should be used during pregnancy only if the potential benefits are considered to justify the potential risks to the fetus. The use during pregnancy should be carefully considered by a healthcare professional.

How should Meprol be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates that Meprol must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F). The medication must be protected from excess heat, moisture, and light to maintain product stability and potency. It is mandatory to keep the container tightly closed and to store the medication in a secured location that is out of the sight and reach of children.

For disposal, the primary method for unused or expired Meprol is an authorized drug take-back program. If a take-back program is unavailable, the medicine should be removed from its container, mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a bag, and then discarded in the household trash. The product must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Meprol found in:

A-Z Index: